IM Cannabis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

IM Cannabis hat ein Gesamteigenkapital von CA$8.3M und eine Gesamtverschuldung von CA$12.3M, was einen Verschuldungsgrad von 147.9% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$41.1M bzw. CA$32.8M.

Wichtige Informationen

147.9%

Verhältnis von Schulden zu Eigenkapital

CA$12.34m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$1.05m
Eigenkapital	CA$8.34m
Gesamtverbindlichkeiten	CA$32.77m
Gesamtvermögen	CA$41.11m

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

Dec 24

Recent updates

Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk

Jul 19

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

Dec 24

Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)

Feb 05

What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?

Jan 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IMCCDie kurzfristigen Aktiva des Unternehmens (CA$20.0M) decken seine kurzfristigen Passiva (CA$30.5M) nicht.

Langfristige Verbindlichkeiten: IMCCDie kurzfristigen Vermögenswerte des Unternehmens (CA$20.0M) übersteigen seine langfristigen Verbindlichkeiten (CA$2.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IMCCDie Nettoverschuldung im Verhältnis zum Eigenkapital (135.4%) wird als hoch angesehen.

Schulden abbauen: IMCCDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 16.5% auf 147.9% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: IMCC verfügt auf der Grundlage des zuletzt gemeldeten freien Cashflows über eine ausreichende Liquiditätsreserve für 4 Monate. [freien Cashflow]], hat aber seitdem zusätzliches Kapital aufgenommen.

Vorhersage Cash Runway: Es wird prognostiziert, dass IMCC auf Grundlage der Schätzungen des freien Cashflows über ausreichend Liquidität für 2 Monate verfügt, das Unternehmen hat seitdem jedoch weiteres Kapital aufgenommen.

IM Cannabis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

Recent updates

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: CA$0.74 loss per share (vs CA$3.14 loss in FY 2022)

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction.

IM Cannabis Announces Receipt of Court Action

Third quarter 2023 earnings released: CA$0.16 loss per share (vs CA$0.59 loss in 3Q 2022)

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2023 Results on Nov 13, 2023

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

New major risk - Market cap size

Second quarter 2023 earnings released: CA$0.26 loss per share (vs CA$0.49 loss in 2Q 2022)

IM Cannabis Corp. to Report Q2, 2023 Results on Aug 14, 2023

Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk

New major risk - Financial position

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

New major risk - Share price stability

IM Cannabis Corp. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: CA$3.13 loss per share (vs CA$3.07 loss in FY 2021)

Price target decreased by 72% to CA$3.45

IM Cannabis Corp. Commences Exit of Canadian Cannabis Market to Focus its Resources on Pursuing Growth Opportunities in Israel, Germany and Europe

IM Cannabis Corp. to Report Q3, 2022 Results on Nov 14, 2022

High number of new directors

High number of new directors

CEO & Director recently bought CA$157k worth of stock

Executive Chairman recently bought CA$105k worth of stock

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. announced that it expects to receive $5 million in funding

Second quarter 2022 earnings released: CA$0.27 loss per share (vs CA$0.10 loss in 2Q 2021)

IM Cannabis Corp., Annual General Meeting, Oct 20, 2022

IM Cannabis Corp. to Report Q2, 2022 Results on Aug 15, 2022

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

First quarter 2022 earnings released: CA$0.14 loss per share (vs CA$0.11 profit in 1Q 2021)

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

IM Cannabis Corp. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to CA$6.00

High number of new and inexperienced directors

CEO & Director recently bought CA$423k worth of stock

Full year 2021 earnings released: CA$0.31 loss per share (vs CA$0.74 loss in FY 2020)

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

IM Cannabis Corp. Provides Earnings Guidance for Fourth Quarter of 2021 and Full Year 2022

Price target decreased to CA$7.63

Third quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.017 profit in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Insider recently sold CA$76k worth of stock

Second quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in 2Q 2020)

Price target decreased to CA$9.50

IM Cannabis Corp. Unveils Proprietary Data from A Clinical Survey Evaluating Medicinal Cannabis Therapy

First quarter 2021 earnings released: EPS CA$0.11 (vs CA$0.011 loss in 1Q 2020)

IM Cannabis Corp. Provides Earnings Guidance for the Second Quarter of 2021

Full year 2020 earnings released: CA$0.74 loss per share (vs CA$0.23 loss in FY 2019)

IM Cannabis Corp. Provides Preliminary Earnings Guidance for the First Quarter and Second Quarter of 2021

IM Cannabis Corp. (CNSX:IMCC) completed the acquisition of Trichome Financial Corp. (CNSX:TFC) from Cresco Labs Inc., Opaskawayak Cree Nation and others.

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. to Bring Canadian Premium Indoor High-THC Medical Cannabis to Israel with Imports from GTEC Holdings Ltd

New 90-day high: CA$12.00

IM Cannabis Corp. Announces Board Changes

Director recently sold CA$120k worth of stock

Director recently sold CA$50k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)

What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?

New 90-day high: CA$2.44

New 90-day high: CA$1.84

New 90-day high: CA$1.72

IM Cannabis Corp Announce That the Israeli Ministry of Health Has Launched A New Pilot Program

New 90-day low: CA$1.11